First clinical experience with 225 Ac-PSMA-617 demonstrates promising antitumor activity with a 63%-70% PSA >50% -response rate, 10-15 months duration of response and complete remissions in approximately ten percent of patients, some …

Targeted alpha particle therapy (TAT) has emerged as a promising strategy for the treatment of prostate cancer (PCa). Actinium-225 (225 Ac), a potent alpha-emitting radionuclide, may be incorporated into targeting vectors, causing robust and in …

Actinium-225 (Ac-225) labelled PSMA RLT has been tested recently in metastatic castration-resistant prostate cancer (mCRPC), with encouraging results. Ac-225, being an alpha emitter, is expected to have higher efficacy and fewer side effects compared to …

This is a Phase 1, open-label, international, dose escalation study to evaluate the safety of \ [225Ac\]Ac-PSMA-617 (225Ac-PSMA-617) in men with PSMA-positive prostate cancer who have and have not had prior exposure to \ [177Lu\]Lu-PSMA-617 (177Lu-PSMA-617) or \ [177Lu\]Lu-PSMA I\&T (177Lu-PSMA I\&T).

Recently, promising results of the antitumor effects were observed in patients with metastatic castration-resistant prostate cancer treated with 177 Lu-labeled PSMA-ligands. Radionuclide therapy efficacy may even be improved by using the alpha emitter Ac-225.

Mar 5, 2025 · This is an open label, phase I/II, multi-center study in adult participants with metastatic hormone sensitive prostate cancer (mHSPC) and with metastatic castration resistant prostate cancer (mCRPC) who have received prior anti-cancer treatment and have a positive 68Ga-PSMA-11 PET scan.

1 day ago · Overall survival and progression-free survival outcomes appear similar for lutetium-177 and actinium-225 in select patients with mCRPC, with some differences between radioligand therapies. PSMA ...

Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an α-radionuclide-labeled PSMA ligand.

Dec 1, 2016 · Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an α-radionuclide–labeled PSMA ligand.

Feb 18, 2025 · Background: Actinium-225 (Ac-225)-based, prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) represents a promising treatment modality for prostate cancer.